HIF1A and ovarian cancer: In this context, our present observation that the clinically relevant dose of PX-478 (25 μM) potently inhibits the invasive migration of ovarian cancer cells (Figure 8) further establishes the therapeutic potential of the LPA-Gai-HIF1α signaling node (Figure 9), especially in HIF1α overexpressing ovarian cancers.